Ed Hemwall, Ph.D.

Edwin (Ed) Hemwall, Ph.D. brings over 40 years of industry experience to consulting services in OTC product development. He focuses on Rx-to-OTC switch, medical claims, regulatory strategy, and FDA Advisory Committee preparation. His prior industry career spanned a range of clinical and regulatory leadership roles with Merck, J&J, GSK and Bayer, retiring in 2016 as a VP on Bayer’s worldwide R&D team. Ed has published and lectured as a Switch and Self-Care advocate and has served on FDA’s Clinical Pharmacology and Pharmaceutical Sciences Advisory Committee, the Board of Directors of CHPA, and as Chair of CHPA’s Regulatory and Scientific Affairs Committee.  In 2023 Ed was honored with the CHPA Regulatory and Scientific Career Achievement Award recognizing outstanding service and contributions to the consumer healthcare products industry having created long-lasting impacts in support of public health.